What move does the options market price into Revolution Medicines's report?

Implied ±22.7%, either direction · provisional.

RVMDNasdaqBiological Products, (No Diagnostic Substances)

Revolution Medicines, Inc. (RVMD) earnings date, market-implied expected move, and options open interest by expiry

186.06

−13.64 · −6.83%

Regular session13:00 ET

Open212.08Volume2.6MMkt cap$43.2BEPS-9.15

Day184.12 – 215.006%52-wk58.00 – 224.3177%

RVMD

Revolution Medicines, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

Inputs

±22.7%implied · straddle

154.35245.05

spot 199.70exp Mar 19ATM strike 200ATM straddle 53.35IV 49%

Nov 4 closeprovisional

Expected move

Inputs

Next report

Feb 24

after close · in 111 days

est.Q4 FY26

Calendar

Next report

Last report

Nov 4

after close

confirmedQ3 FY26Nov 4 close

Implied vs realized

Linked news

1dRPRX · customerRoyalty Pharma posts Q3 net income $266,637 thousand; nine-month net $816,379 thousand
6dSNY · customerSanofi Q3 sales €14,444 million, business EPS €3.55; upgrades 2026 guidance

News

Largest filed tie

13F top-10 QoQ

+23.58%

shares held · 10 largest managers

13F · Jun 30 '26128d lag

700 managers

Top fund weight

1.20%

RVMD weight · XBI

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Revolution Medicines (RVMD) is expected to report on Feb 24 after close (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Aug 5 '26confirmed±7.9%▲+0.26%×0.03

quarterimplied−10%0+10%realized×

Q2 FY26±7.9%▲+0.26%×0.03

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 4 close

0.69OI · 4 expiries · Nov 4 closeP/C open interest · Mar 19 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

3,901+2%Nov 2015d1.063,687−1%1.06

6,7270%Dec 1843d1.414,755+2%1.41

3,9950%Jan 1571d0.3611,202−2%0.36

report · Feb 24 · after close · est.

6660%Mar 19134d9670%

ExpiryPutsCallsP/C

Nov 2015d3,901+2%3,687−1%1.06

Dec 1843d6,7270%4,755+2%1.41

Jan 1571d3,9950%11,202−2%0.36

report · Feb 24 · after close · est.

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

scenario · straddle±22.7%

Funds 3

XBI±0.3%

VTI±0.0%

VT±0.0%

Dashed = straddleMethod Source: SEC filings · N-PORT · market data

Linked exposure

Revenue flow

as filedQ3 FY26

−206.25%as filednet margin

Revenue$198M—

Gross profit$197M99.83%—

Operating income−$373M−188.88%+26.13%

Pre-tax income−$410M+36.40%

Net income−$407M−206.25%+36.77%

Cost of revenue$327,000—

Operating expenses$570M+12.92%

Tax−$2M—

Other expense−$37M+73.67%

Source: SEC filings · standardized · QE Sep 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Long dash = implied range · Nov 4 close · Hatch = extended hours · ▯ up · ▮ downSource: market data · 13:00 ET

Intraday

Event sensitivity

NFP ×1.15· ±2.6% vs ±2.2% · 10 releases

eventrelease day|move|up · n×base

NFPjobs report±2.6%5 of 10×1.15

PPIproducer prices±2.2%4 of 10×0.97

GDPgross domestic product±2.1%12 of 19×0.93

PCEpersonal income & outlays±1.9%12 of 19×0.83

FOMCrate decision±1.8%13 of 24×0.80

CPROFcorporate profits±1.7%8 of 12×0.76

CPIconsumer prices±1.1%6 of 10×0.49

Bar = avg |move| to ±3% · tick = ±2.2% avg day · ×base = |move| ÷ ±2.2% · min 6 releases

Earnings history

EPS -1.90 · consensus —

Quarter	Reported	EPS	Consensus
Q3 FY26	—	-1.90	—
Q2 FY26	Aug 5 '26 · confirmed	-3.06	—
Q1 FY26	—	-2.29	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod